While the field was previously constrained by the lack of other syngeneic, immunocompetent murine models, a potentially novel syngeneic murine RCC cell line, LVRCC67, was developed recently by engineering the loss of Vhl, p53, and Rb1 and the overexpression of c-myc (41). This evidence concerns the gene TP53 and renal cell carcinoma.